Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5221139 | 0.93 | GPR119 (0.39) | GPR119PIK3CAHPGDPIK3R1SCN9A | |
| SCHEMBL5217508 | 0.90 | GPR119 (0.40) | GPR119PIK3CAHPGDPIK3R1KDM4E | |
| SCHEMBL5217513 | 0.90 | GPR119 (0.40) | GPR119PIK3CAHPGDPIK3R1KDM4E | |
| SCHEMBL5222010 | 0.88 | GPR119 (0.40) | GPR119PIK3CAHPGDNR1H2SCN9A | |
| SCHEMBL5223395 | 0.87 | PDE4B (0.39) | GPR119PIK3CAHPGDKDM4EALDH1A1 | |
| SCHEMBL5220801 | 0.85 | PIK3CA (0.34) | GPR119PIK3CAHPGDPIK3R1AKT1 | |
| SCHEMBL5220796 | 0.85 | PIK3CA (0.34) | GPR119PIK3CAHPGDPIK3R1AKT1 | |
| SCHEMBL5760348 | 0.85 | GPR119 (0.42) | GPR119PIK3CAPIK3R1NR1H2GABRA5 | |
| SCHEMBL5222905 | 0.85 | P2RX3 (0.40) | GPR119PIK3CAPIK3R1 | |
| SCHEMBL5220102 | 0.84 | GPR119 (0.39) | GPR119PIK3CAPIK3R1NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1641796-B1 | 5HT2C RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | HOFFMANN LA ROCHE (CH) | 2007-06-06 | — | — | EP | disclosed |
| US-7208494-B2 | 5HT2c receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2007-04-24 | — | — | US | disclosed |
| EP-1641796-A1 | 5HT2C RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-05 | — | — | EP | disclosed |
| US-20050026925-A1 | 5HT2c receptor agonists | HOFFMANN-LA ROCHE INC. | 2005-02-03 | — | — | US | disclosed |
| WO-2005000849-A1 | 5HT2C RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026925-A1 | 5HT2c receptor agonists | HTR2C, HTR2A, HTR5A | GPR119 17/4885PIK3CA 3003/4885HPGD 1891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.